蔚蓝生物获得新兽药注册证书

Core Viewpoint - The company has received approval from the Ministry of Agriculture and Rural Affairs for its new veterinary drug, "Mirtazapine Ointment," which addresses significant clinical signs in cats such as decreased appetite and weight loss, potentially leading to severe health issues if untreated [1] Group 1: Product Development - The company, along with its subsidiaries, has successfully developed a new veterinary drug classified as a Category V new veterinary drug, which has been officially registered [1] - The new product, Mirtazapine Ointment, is designed to meet clinical needs in the pet market, particularly for cats experiencing appetite loss [1] Group 2: Product Characteristics - The Mirtazapine Ointment is characterized by controllable quality, safety and effectiveness, ease of administration, and high compliance [1] Group 3: Market Context - Currently, the company has not been able to find any information regarding the sales status and market share of similar products in circulation through public channels [1]